Antares, Novartis pursuing undruggable cancer targets in $1.9B deal
· jennifer boggs
AI Briefing
- • Antares Therapeutics partners with Novartis for $1.9B deal to discover cancer treatments for undruggable targets.
- • Collaboration includes $105 million up-front payment and aims to develop small-molecule programs.
- • Partnership marks Antares' first collaboration since spinning out of Scorpion Therapeutics last year.
Context
Antares Therapeutics Inc has entered a collaboration with Novartis AG worth up to $1.9 billion. The deal includes a $105 million up-front payment. The partnership aims to discover small-molecule programs against certain cancer targets.
The targets in question are considered undruggable in oncology. This collaboration is Antares' first partnership since it spun out of Scorpion Therapeutics Inc about a year ago.
Advertisement